Group Effect in Full Replicate Design [RSABE / ABEL]

posted by GM – India, 2018-09-12 12:32  – Posting: # 19271
Views: 1,491

Dear Helmut,

Thank you for the quick reply.

» Which agency’s guidance?

FDA Guidance only.

» What do you mean by “checked”? Have group – together with some nested terms – as part of the model (only report the MSEs, p-values) or do you additionally want to base any decision on it? That’s not a good idea, since power might be compromised and the Type I Error inflated (see this presentation).

Sorry for poor english.

» If so, what are the fixed/random effets need to be checked in RSABE and ABE?
  • EMA: all effects fixed
  • FDA: all effects fixed except subject(group × sequence) random

We understand the above and this is as same as 2x2 design. But we thought this is only for ABE approach.

For RSABE approch, only sequence effect will be sufficient in the model? or any group terms need to be include here.

Thank you in Advance.

Best Regards,

Complete thread:

 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
19,405 posts in 4,122 threads, 1,323 registered users;
online 6 (0 registered, 6 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 04:22 CEST

[Those] who have an excessive faith in their theories or in their
ideas are not only poorly disposed to make discoveries, but they
also make very poor observations.    Claude Bernard

BEBAC Ing. Helmut Schütz